#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	5982	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2344	571.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1373	1373	C	619	C,A,G	581,7,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8990	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4318	507.3	0	.	n	.	0	T695C	SNP	695	695	T	1465	1465	C	587	C,A,T,G	560,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8990	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4318	507.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	2107	2107	A	622	A,C	601,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8990	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4318	507.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2741	2741	C	662	C,T,A	632,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8990	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4318	507.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2815	2815	A	669	A,C	644,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8990	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4318	507.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3367	3367	C	579	C,T	560,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	712	folP	852	852	100.0	folP.l15.c4.ctg.1	2311	75.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1395	1397	AGC	75;74;74	A;G;C	70;70;70	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	155	1366	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4124	81.0	1	SNP	p	S91F	0	.	.	271	273	TCC	955	957	TCC	75;75;75	T;C;C,G	64;72;71,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	155	1366	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4124	81.0	1	SNP	p	D95N	0	.	.	283	285	GAC	967	969	GAC	77;77;78	G;A;C	74;75;76	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	155	1366	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4124	81.0	1	SNP	p	D95G	0	.	.	283	285	GAC	967	969	GAC	77;77;78	G;A;C	74;75;76	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	155	1366	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4124	81.0	0	HET	.	.	.	G2377A	.	2377	2377	G	3061	3061	G	69	G,A	37,9	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	532	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	2052	64.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	818	820	ACC	114;116;115	A,C;C;C,T	110,1;115;113,1	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	532	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	2052	64.3	0	.	p	.	0	R44H	NONSYN	130	132	CGC	833	835	CAC	116;116;117	C;A;C	106;102;110	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	532	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	2052	64.3	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	1016	1018	CAC	121;121;121	C,A;A,C;C,A	119,2;114,6;118,2	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	532	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	2052	64.3	1	SNP	p	G45D	0	.	.	133	135	GGC	836	838	GGC	117;118;119	G;G;C	110;112;113	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	384	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1753	53.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1564	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3408	110.9	1	SNP	p	D86N	0	.	.	256	258	GAC	814	816	GAC	86;86;87	G;A;C,A	66;51;60,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1564	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3408	110.9	1	SNP	p	S87R	0	.	.	259	261	AGT	817	819	AGT	86;87;91	A,C;G;T,A,G	57,1;68;77,2,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1564	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3408	110.9	1	SNP	p	S87W	0	.	.	259	261	AGT	817	819	AGT	86;87;91	A,C;G;T,A,G	57,1;68;77,2,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1564	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3408	110.9	1	SNP	p	S87I	0	.	.	259	261	AGT	817	819	AGT	86;87;91	A,C;G;T,A,G	57,1;68;77,2,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1564	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3408	110.9	1	SNP	p	S88P	0	.	.	262	264	TCC	820	822	TCC	91;92;90	T,G,C;C,T;C	80,1,1;82,4;84	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1540	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3605	104.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	2006	2008	GGC	123;123;124	G,A;G;C	112,1;111;111	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	283	1084	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2949	88.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1669	1671	GCA	138;139;139	G,A;C;A	128,2;131;132	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	283	1084	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2949	88.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1672	1674	ATC	139;139;138	A;T,A;C	132;134,1;133	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	283	1084	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2949	88.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1684	1686	GTG	136;136;136	G,C;T,C;G	131,1;127,1;131	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	283	1084	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2949	88.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1684	1686	GTG	136;136;136	G,C;T,C;G	131,1;127,1;131	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	283	1084	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2949	88.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2188	2190	ACC	63;63;62	A,C;C;C,G	46,1;56;55,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	283	1084	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2949	88.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2242	2244	GCG	58;58;58	G;C,G;G,C	44;42,1;46,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	283	1084	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2949	88.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2242	2244	GCG	58;58;58	G;C,G;G,C	44;42,1;46,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	283	1084	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2949	88.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2365	2367	GGC	60;60;60	G;G,T;C,T,A	56;55,1;49,5,3	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	283	1084	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2949	88.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2374	2376	GGC	60;61;61	G;G;C,G,A	53;42;30,1,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	283	1084	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2949	88.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2392	2394	CCG	63;60;60	C;C,G;G,C,A	49;43,1;48,2,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1650	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3839	103.8	1	SNP	p	L421P	0	.	.	1261	1263	CTG	2009	2011	CTG	137;137;138	C,G,T;T,C,G;G,T,C	102,8,1;122,3,2;125,2,2	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	632	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2595	59.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	970	970	C	45	C,A	34,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	618	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2503	60.7	0	.	p	.	0	E48G	NONSYN	142	144	GAA	901	903	GGA	108;108;108	G;G,A;A	104;104,1;105	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	618	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2503	60.7	0	.	p	.	0	F135L	NONSYN	403	405	TTT	1162	1164	CTT	82;89;89	C;T;T,G	77;84;87,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	618	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2503	60.7	0	.	p	.	0	R143G	NONSYN	427	429	AGA	1186	1188	GGA	96;97;96	G,A;G;A	86,1;91;85	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	618	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2503	60.7	0	.	p	.	0	D171G	NONSYN	511	513	GAT	1270	1272	GGT	105;105;103	G;G,A;T,G,A	102;101,1;99,1,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	618	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2503	60.7	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1324	1326	AGC	119;119;118	A;G;C,G	111;110;110,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	618	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2503	60.7	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1390	1390	T	108	T,C	104,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	618	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2503	60.7	1	SNP	p	G120K	0	.	.	358	360	GGT	1117	1119	GGT	80;80;78	G;G,T;T,G,A	76;72,1;65,2,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	618	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2503	60.7	1	SNP	p	A121D	0	.	.	361	363	GCC	1120	1122	GCC	78;78;78	G,T;C;C	70,1;71;74	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	618	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2503	60.7	1	SNP	p	A121N	0	.	.	361	363	GCC	1120	1122	GCC	78;78;78	G,T;C;C	70,1;71;74	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3114	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5530	138.0	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2347	2349	AAT	158;157;157	A;A;T,A	154;152;153,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	474	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1782	66.1	1	SNP	p	V57M	1	.	.	169	171	ATG	900	902	ATG	141;140;141	A;T;G	133;137;138	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
